Table 2 Sites and causes of infection in the primary efficacy population
Variable | Alternative therapy (n = 206) | Standard therapy (n = 227) | Total (n = 433) | P-value* |
|---|---|---|---|---|
Primary site of infection, n (%): | 0.410 | |||
Lung | 106 (51.5) | 87 (38.3) | 193 (44.6) | |
Abdomen | 46 (22.3) | 64 (28.2) | 110 (25.4) | |
Urinary tract | 26 (12.6) | 28 (12.3) | 54 (12.5) | |
Skin | 9 (4.4) | 15 (6.6) | 24 (5.5) | |
Blood | 9 (4.4) | 12 (5.3) | 21 (4.8) | |
Other† | 10 (4.9) | 21 (9.3) | 31 (7.2) | |
Source of infection, n (%): | 0.923 | |||
Community | 158 (76.7) | 175 (77.1) | 333 (76.9) | |
Nosocomial | 48 (23.3) | 52 (22.9) | 100 (23.1) | |
Type of infecting agent‡, n (%): | ( n = 163) | ( n = 168) | ( n = 331) | |
Fungal | 20 (12.3) | 16 (9.5) | 36 (10.9) | |
Gram-negative | 75 (46.0) | 91 (54.2) | 166 (50.2) | |
Gram-positive | 82 (50.3) | 91 (54.2) | 173 (52.3) | |
Mixed aerobic/anerobic | 7 (4.3) | 9 (5.4) | 16 (4.8) | |
Viral | 3 (1.8) | 1 (0.6) | 4 (1.2) | |
Other | 4 (2.5) | 8 (4.8) | 12 (3.6) |